GLP-1 and Incretin Therapeutics
An evidence-graded strategy report. Regulatory and evidence status summarized as of June 2026.
A platform, read carefully
GLP-1 and incretin therapies are a clear example of metabolic platform medicine: a single mechanism reaching glucose control, body weight, cardiovascular and kidney risk, and — most recently — liver disease. They are one of the most consequential drug developments of the past decade, and a useful case study in how evidence-graded analysis separates real platform value from momentum.
This is one report within a broader metabolic-disease practice — not the whole of what Valdez BioStrategy works on. It is published here as a worked example of method: approved indications held apart from trial evidence and from emerging frontiers, and mechanism read carefully against outcome.
Strategic questions most reports miss
Most GLP-1 coverage stops at weight and HbA1c. The questions that actually shape development and positioning sit one layer deeper.
On-drug gains are not the same as lasting change Peer-reviewed
Incretin therapy sharply improves insulin secretion while it is taken; much of that gain reverses after stopping. Read durability with care — do not assume lasting change.
Timing may matter more than dose Peer-reviewed · on-treatment
The strongest prevention signal comes from early treatment — but it reflects risk reduction during therapy, not a permanent change.
Glucagon control is indirect Established mechanism
GLP-1 restrains glucagon through neighboring islet cells, not by acting directly on the alpha-cell — which helps explain why responses vary.
The economic question is maintenance, not initiation Open question
No trial has rigorously tested whether a lower maintenance dose can hold benefits at lower cost.
Microdosing is a consumer trend, not a clinical strategy No RCT evidence
It lacks randomized evidence and carries real risks; plausible is not the same as demonstrated.
These are the questions our next Strategy Report takes up in depth — graded by evidence, not hype. Educational summary only; not medical or investment advice.
From lizard venom to platform medicine
The incretin concept is more than a century old, but the drug era began with a lizard: in 1992, exendin-4 was isolated from Gila monster venom, and its resistance to rapid breakdown solved the problem that had kept the body's own GLP-1 from becoming a medicine.
A fuller, dynamic timeline is a planned enhancement to this report.
A competitive field, read by mechanism and evidence
The space is led by a small number of companies, with a widening set of fast-followers and biotech entrants. Differentiation is playing out across molecule design, route of administration (injectable vs. oral small molecule), efficacy ceiling (mono- to dual- to triple-agonism), tolerability, durability, and manufacturing.
Where market sizing comes up, we treat it as an analyst estimate — attributed and clearly labeled, never a forecast to act on. Our role is scientific and strategic diligence: reading the evidence, the mechanism, and the competitive set. This report is not investment advice and contains no revenue projections.
Molecules, companies, and differentiation
Who owns which molecules, what each contributed, and where the competition is actually playing out — qualitative positioning only.
Novo Nordisk
Molecules: semaglutide, liraglutide
Contribution: the broadest outcomes portfolio across glucose, weight, cardiovascular risk, kidney disease, and MASH. Differentiation: organ-protection evidence, lifecycle and dose expansion, and brand depth.
Investor relations ↗Eli Lilly
Molecules: tirzepatide, orforglipron, retatrutide
Contribution: efficacy escalation through dual and (reported) triple agonism, plus the first oral small-molecule GLP-1. Differentiation: efficacy ceiling, modality expansion, and manufacturing/scalability potential.
Investor relations ↗CHALLENGERS & APPROACHES
WHERE DIFFERENTIATION IS PLAYING OUT
Company profiles are provided for context only. This report is not investment advice and does not evaluate securities. Investor-relations links point to each company's official site; market values and financials are intentionally not reproduced here.
A timeline of trials that defined the field
The class has one of the deepest trial portfolios in metabolic medicine — and not every trial was positive, which is itself informative. Select a milestone to expand its design, result, evidence stage, and sources.
Chronological, 2016–2026: cardiovascular outcomes → obesity → organ protection (kidney, liver) → triple agonism.
2016LEADERNovo NordiskPeer-reviewed
~13% reduction in major cardiovascular events (HR 0.87); cardiovascular death reduced ~22%. The first GLP-1 agent to demonstrate a cardiovascular benefit.
2016SUSTAIN-6Novo NordiskPeer-reviewed
~26% reduction in major cardiovascular events (HR 0.74). Established weekly semaglutide as cardiovascular-protective in type 2 diabetes.
2017EXSCELAstraZenecaPeer-reviewed
Neutral cardiovascular result (HR 0.91; 95% CI 0.83–1.00; not statistically significant). A reminder that cardiovascular benefit is not a uniform class effect — it tracks with the more potent agents.
2019REWINDEli LillyPeer-reviewed
~12% reduction in major cardiovascular events (HR 0.88). Extended the cardiovascular signal into a broad, mostly primary-prevention population.
2021STEP 1Novo NordiskPeer-reviewed
~14.9% mean weight loss over 68 weeks. Reset expectations for what pharmacologic weight loss could achieve.
2022SURMOUNT-1Eli LillyPeer-reviewed
~20.9% mean weight loss (15 mg). Dual GIP/GLP-1 agonism surpassed monoagonist weight loss. Its diabetes-prevention finding reflects risk reduction during ongoing treatment, not a permanent effect.
2023SELECTNovo NordiskPeer-reviewed
~20% reduction in major cardiovascular events (HR 0.80). Extended cardiovascular benefit to people without diabetes; basis for the cardiovascular-risk label.
2023STEP-HFpEFNovo NordiskTrial evidence only
Improved heart-failure symptoms, physical function, and weight (KCCQ and 6-minute walk distance). Trial evidence only — not an FDA-approved HFpEF indication; not powered for hospitalization or mortality.
2024FLOWNovo NordiskPeer-reviewed
~24% reduction in kidney-disease outcomes (HR 0.76). First dedicated GLP-1 kidney-outcomes trial; supports the CKD-in-T2D approval.
2024STEP 9Novo NordiskTrial evidence only
Reduced knee osteoarthritis pain (WOMAC) alongside weight loss. Trial evidence only — not an FDA-approved osteoarthritis indication.
2025ESSENCENovo NordiskPeer-reviewed
MASH resolution 62.9% vs. 34.3%; fibrosis improvement 36.8% vs. 22.4%. Basis for the 2025 FDA accelerated approval in noncirrhotic MASH (F2–F3); confirmatory data pending.
2026TRIUMPH-1Eli LillyCompany topline
~28% mean weight loss at 80 weeks (company-reported). Company topline data; peer-reviewed publication pending — not yet peer-reviewed or FDA-reviewed. Treat as provisional.
Each milestone links to its peer-reviewed publication and ClinicalTrials.gov registry; FDA approval pages are linked only where an approval exists. Status as of June 2026.
Approved, investigational, and emerging
The same platform spans very different levels of evidence. We separate FDA-confirmed indications from promising trial findings and from early-stage frontiers — because that distinction drives nearly every diligence decision.
FDA-approved Regulator-confirmed
On-label indications backed by FDA decisions.
- Type 2 diabetes — multiple agents
- Chronic weight management — semaglutide, tirzepatide, others
- Cardiovascular risk reduction, where approved — e.g., semaglutide (SELECT)
- Chronic kidney disease in type 2 diabetes — semaglutide (FLOW, 2025)
- Obstructive sleep apnea in obesity — tirzepatide (2024)
- MASH, noncirrhotic F2–F3 — accelerated approval (2025)
- Orforglipron (Foundayo) — oral small-molecule GLP-1 (2026)
- High-dose semaglutide 7.2 mg (Wegovy HD) — (2026)
- Oral semaglutide 25 mg for weight management — (2025)
Strong trial evidence Not an approved indication
Positive trials that are not (yet) FDA-approved uses.
- Obesity-related HFpEF — STEP-HFpEF (symptom & function benefit; not powered for hospitalization or mortality)
- Knee osteoarthritis pain — STEP 9
- Triple agonism (retatrutide), Phase 3 — TRIUMPH Company topline
Emerging frontiers Investigational
Early or hypothesis-stage; mechanistically interesting, not proven.
- Addiction / substance use
- Neurodegeneration (e.g., EVOKE, ongoing)
- Inflammation / immune modulation
- Long-acting and durable delivery
- Individualized response prediction
- Lean-mass preservation strategies
Regulatory and evidence status summarized as of June 2026. Status changes quickly; claims are labeled by evidence stage.
Separating direct effects from downstream benefit
A recurring error in metabolic strategy is treating "the drug helps an organ" as "the drug acts directly on that organ." We keep the two apart and label the strength of the evidence — because target and trial decisions depend on it.
Islet — direct, with an indirect twist Established
Glucose-dependent insulin secretion from the beta cell is a well-established, direct effect. Glucagon suppression, however, is substantially indirect — mediated through intra-islet signaling, including delta-cell somatostatin and alpha–beta–delta crosstalk — rather than dominated by direct alpha-cell receptors.
Liver — benefit likely largely indirect Contested
Hepatic improvements are real at the outcome level, but direct GLP-1 receptor expression on hepatocytes is contested. The benefit is best read as largely indirect — via weight loss, improved insulin sensitivity, and effects on non-parenchymal liver cells.
Heart — multifactorial, not simple inotropy Contested
Cardiovascular benefit likely reflects weight, blood pressure, inflammation, and vascular/endothelial effects, plus selected direct mechanisms. Direct working-cardiomyocyte receptor activation and inotropy should not be overstated.
This is where Valdez BioStrategy adds value: distinguishing mechanism from outcome, and labeling each claim by the strength of its evidence, so that decisions rest on what is actually known.
Safety and real-world limitations
Powerful therapies, but not consequence-free. A credible strategy weighs the limitations as carefully as the benefits.
Real-world considerations. Gastrointestinal effects (nausea, vomiting, diarrhea, constipation) are common but usually transient and dose-related. Benefits depend on continued treatment — weight is regained after stopping. Lean-mass loss during rapid weight loss is an active concern. Gallbladder disease is modestly increased. A boxed warning for thyroid C-cell tumors is carried based on rodent data; a pancreatitis signal has not been causally confirmed in large trials. None of this replaces clinical judgment.
What we're watching Investigational
- How much organ protection is direct versus weight-mediated?
- Can lean mass be preserved during pharmacologic weight loss?
- Can response be predicted and individualized?
- Are there meaningful CNS effects — in addiction or neurodegeneration?
- Can durability and access be engineered to outlast dosing?
Educational summary only — not medical advice, investment advice, or drug promotion. Claims are labeled by evidence stage, and regulatory status is date-stamped because the field is moving quickly.
Evaluating a metabolic-disease asset?
For confidential biotech, spinout, investor, or strategic diligence inquiries, start with a brief scoping conversation.
Request a confidential scoping callPrefer email? contact@valdezbiostrategy.com